Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3560505 | 0.88 | CYP1A2 (0.41) | CYP1A2CYP2C19ALDH1A1EGFRERBB2 | |
| SCHEMBL3554231 | 0.80 | S1PR2 (0.56) | CYP1A2S1PR2PRKCIKDM4ERAB9A | |
| SCHEMBL8673571 | 0.80 | SMN1; SMN2 (0.52) | CYP1A2CYP2C19ALDH1A1KDM4ERAB9A | |
| SCHEMBL30797163 | 0.76 | NPSR1 (0.56) | EGFRERBB2CNR1KDM4EMAPT | |
| SCHEMBL10192079 | 0.76 | CNR1 (0.63) | CYP1A2CYP2C19ALDH1A1CNR1RAB9A | |
| SCHEMBL3781565 | 0.74 | ALDH1A1 (0.67) | ALDH1A1EGFRERBB2CNR1RAB9A | |
| SCHEMBL4319453 | 0.73 | GAA (0.57) | CYP1A2CYP2C19ALDH1A1CNR1GAA | |
| SCHEMBL4853400 | 0.73 | HTT (0.60) | CYP2C19ALDH1A1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL2958982 | 0.72 | MDM2 (0.62) | KDM4ERAB9AROCK2CDK2ROCK1 | |
| SCHEMBL10802920 | 0.72 | CNR1 (0.63) | CYP2C19ALDH1A1CNR1KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| CN-1856305-B | Pyridine derivatives as urotensin II antagonists | ACTELION PHARMACEUTICALS LTD | 2010-04-28 | — | — | CN | disclosed |
| EP-1670470-B1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-04-08 | — | — | EP | disclosed |
| EP-1670470-B1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
| CN-1856305-A | Pyridine derivatives and their use as urotensin II antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-01 | — | — | CN | disclosed |
| EP-1670470-A1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030209-A1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | CYP1A2 918/4885CYP2C19 595/4885ALDH1A1 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.